Dr. Rik Mehta, Co-Founder of Lactiga, joins EisnerAmper's TechTalk host Fritz Spencer to discuss how his biotech startup is pioneering the development of the first mucosal antibodies to treat the unmet medical needs of immunodeficient patients. In this episode, discover how Lactiga is unlocking the full therapeutic value of human milk to create this next generation of anti-infectives. Tune in to learn more about the startup’s mission to give immunodeficient patients a new line of defense against pathogens, significantly improving their quality of life and offering hope for a healthier future.